Self-report methodology for quantifying standardized cannabis consumption in milligrams delta-9-tetrahydrocannabinol

References

• ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF, 3rd. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci. 2000;45:24–30. doi:10.1520/JFS14636J.
   PubMed Web of Science ®Google Scholar
• Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, Elsohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci. 2019;269:5–15. doi:10.1007/s00406-019-00983-5.
   PubMed Web of Science ®Google Scholar
• Cash MC, Cunnane K, Fan C, Romero-Sandoval EA, Largent-Milnes T. Mapping cannabis potency in medical and recreational programs in the United States. PLoS One. 2020;15:e0230167. doi:10.1371/journal.pone.0230167.
   PubMed Web of Science ®Google Scholar
• Walden N, Earleywine M. How high: quantity as a predictor of cannabis-related problems. Harm Reduct J. 2008;5:20. doi:10.1186/1477-7517-5-20.
   PubMed Web of Science ®Google Scholar
• Kirk JM, De Wit H. Responses to oral Δ9-tetrahydrocannabinol in frequent and infrequent Marijuana users. Pharmacol Biochem Behav. 1999;63:137–42. doi:10.1016/S0091-3057(98)00264-0.
   PubMed Web of Science ®Google Scholar
• Day N, Sambamoorthi U, Taylor P, Richardson G, Robles N, Jhon Y, Scher M, Stoffer D, Cornelius M, Jasperse D, et al. Prenatal marijuana use and neonatal outcome. Neurotoxicol Teratol. 1991;13:329–34.
   PubMed Web of Science ®Google Scholar
• Cuttler C, Spradlin A, Ito E. Measuring cannabis consumption: psychometric properties of the daily sessions, frequency, age of onset, and quantity of cannabis use inventory (DFAQ-CU). PLoS One. 2017;12:e0178194. doi:10.1371/journal.pone.0178194.
   PubMed Web of Science ®Google Scholar
• Freeman TP, Lorenzetti V. ‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration. Addiction. 2020;115:1207–16. doi:10.1111/add.14842.
   PubMed Web of Science ®Google Scholar
• Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depen. 2010;110:137–43. doi:10.1016/j.drugalcdep.2010.02.017.
   PubMed Web of Science ®Google Scholar
• Heishman SJ, Evans RJ, Singleton EG, Levin KH, Copersino ML, Gorelick DA. Reliability and validity of a short form of the Marijuana craving questionnaire. Drug Alcohol Depen. 2009;102:35–40. doi:10.1016/j.drugalcdep.2008.12.010.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Borodovsky JT, Struble CA, Habib MI, Shmulewitz D, Livne O, Aharonovich E, Walsh C, Cuttler C, Hasin DS, et al. Estimating THC consumption from smoked and vaped cannabis products in an online survey of adults who use cannabis. Cannabis Cannabinoid Res. 2022. doi:10.1089/can.2022.0238.
   Google Scholar
• Borodovsky JT, Hasin DS, Shmulewitz D, Walsh C, Livne O, Aharonovich E, Struble CA, Habib MI, Budney AJ. Typical hits, grams, or joints: evaluating cannabis survey measurement strategies for quantifying consumption. Cannabis Cannabinoid Res. 2023. doi:10.1089/can.2022.0237.
   PubMedGoogle Scholar
• Goodman S, Leos-Toro C, Hammond D. Methods to assess cannabis consumption in population surveys: results of cognitive interviewing. Qual Health Res. 2019;29:1474–82. doi:10.1177/1049732318820523.
   PubMed Web of Science ®Google Scholar
• Goodwin RS, Darwin WD, Chiang CN, Shih M, Li SH, Huestis MA. Urinary elimination of 11-nor-9-carboxy- 9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32:562–69. doi:10.1093/jat/32.8.562.
   PubMed Web of Science ®Google Scholar
• Musshoff F, Madea B. Review of biologic matrices (Urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monit. 2006;28:155–63. doi:10.1097/01.ftd.0000197091.07807.22.
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42:327–60. doi:10.2165/00003088-200342040-00003.
   PubMed Web of Science ®Google Scholar
• Lanz C, Mattsson J, Soydaner U, Brenneisen R, Dehghani F. Medicinal cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PLoS One. 2016;11:e0147286. doi:10.1371/journal.pone.0147286.
   PubMed Web of Science ®Google Scholar
• Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. PsycExtra Dataset. 1990;99:42–62.
   Google Scholar
• Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770–804. doi:10.1002/cbdv.200790152.
   PubMed Web of Science ®Google Scholar
• McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage. 2005;10:242516. doi:10.1155/2005/242516.
   Google Scholar
• Mahmoudinoodezh H, Telukutla SR, Bhangu SK, Bachari A, Cavalieri F, Mantri N. The transdermal delivery of therapeutic cannabinoids. Pharmaceutics. 2022;14:438. doi:10.3390/pharmaceutics14020438.
   PubMed Web of Science ®Google Scholar
• Hjorthøj CR, Fohlmann A, Larsen A-M, Arendt M, Nordentoft M. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clin. Addiction. 2012;107:1123–31. doi:10.1111/j.1360-0443.2011.03757.x.
   PubMed Web of Science ®Google Scholar
• Franz S, Skopp G, Boettcher M, Musshoff F. Creatinine excretion in consecutive urine samples after controlled ingestion of water. Drug Test Anal. 2019;11:435–40. doi:10.1002/dta.2514.
   PubMed Web of Science ®Google Scholar
• Kruger DJ, Korach NJ, Kruger JS. Requirements for cannabis product labeling by U.S. State. Cannabis Cannabinoid Res. 2021;7:156–60. doi:10.1089/can.2020.0079.
   PubMedGoogle Scholar